Seungyong Shin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seungyong Shin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Wooram Park
Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University (SKKU), Suwon, Republic of Korea
4 shared publications - Dong-Hyun Kim
Department of Radiology, Feinberg School of Medicine, Northwestern University, Chicago, USA
3 shared publications - Ga‐Hyun Bae
Department of MetaBioHealth Institute for Cross‐disciplinary Studies (ICS) Sungkyunkwan University (SKKU) Seobu‐ro 2066 Suwon Gyeonggi 16419 Republic of Korea
3 shared publications - Joo Dong Park
Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University (SKKU), Seobu-ro 2066, Suwon, Gyeonggi, 16419, Republic of Korea
3 shared publications - Eun‐Young Koh
Department of MetaBioHealth Institute for Cross‐disciplinary Studies (ICS) Sungkyunkwan University (SKKU) Seobu‐ro 2066 Suwon Gyeonggi 16419 Republic of Korea
2 shared publications - Jieun Han
Department of Integrative Biotechnology College of Biotechnology and Bioengineering Sungkyunkwan University (SKKU) Seobu‐ro 2066 Suwon Gyeonggi 16419 Republic of Korea
2 shared publications
Latest Publications
- 13 January 2026
- Published by Elsevier in Biomaterials
- Vol. 330, 124002
Transforming lipid nanoparticles into radio-activatable therapeutics through synergistic ferroptosis for enhanced cancer radiotherapy
- 13 January 2026
- Published by Elsevier in Biomaterials
- Vol. 330, 124002
Transforming lipid nanoparticles into radio-activatable therapeutics through synergistic ferroptosis for enhanced cancer radiotherapy
- Open Access
- 12 November 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (7) , e03748
Photosensitizing Lipid Nanoparticles for Ferroptosis‐Enhanced Photodynamic Cancer Therapy via GPX4 Silencing
Ferroptosis, a regulated form of non‐apoptotic cell death driven by iron‐dependent lipid peroxidation, has emerged as a promising approach for overcoming therapy‐resistant cancers. A multifunctional lipid nanoparticle (LNP) platform was developed to integrate ferroptosis induction with photodynamic therapy (PDT) for synergistic anticancer effects. By partially substituting cholesterol in conventional DLin‐MC3‐DMA (MC3)‐based LNPs with cholesterol—polyethylene glycol (PEG)–pheophorbide a (CPP), we engineered photosensitizing lipid nanoparticles (PLNPs) capable of delivering glutathione peroxidase 4 (GPX4)‐targeting small interfering RNA (siRNA). Upon laser irradiation, the PLNPs generate reactive oxygen species (ROS) through PDT, while siRNA‐mediated GPX4 silencing promotes ferroptosis by disrupting cellular antioxidant defenses. The PLNPs demonstrate favorable physicochemical characteristics, efficient gene silencing, and potent ROS production. In vitro experiments in 4T1 and EO771 breast cancer cells reveal enhanced cytotoxicity under combined treatment, underscoring the synergistic interaction between PDT‐induced oxidative stress and ferroptotic cell death. In vivo, the PLNPs exhibit prolonged tumor retention, effective GPX4 knockdown, and significant tumor growth inhibition, with minimal systemic toxicity. Overall, this work introduces a dual‐function nanoplatform that potentiates photodynamic cancer therapy through ferroptosis induction and offers a versatile strategy for developing next‐generation combination treatments targeting aggressive tumors.
- 12 November 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (7) , e03748
Open AccessPhotosensitizing Lipid Nanoparticles for Ferroptosis‐Enhanced Photodynamic Cancer Therapy via GPX4 Silencing
Ferroptosis, a regulated form of non‐apoptotic cell death driven by iron‐dependent lipid peroxidation, has emerged as a promising approach for overcoming therapy‐resistant cancers. A multifunctional lipid nanoparticle (LNP) platform was developed to integrate ferroptosis induction with photodynamic therapy (PDT) for synergistic anticancer effects. By partially substituting cholesterol in conventional DLin‐MC3‐DMA (MC3)‐based LNPs with cholesterol—polyethylene glycol (PEG)–pheophorbide a (CPP), we engineered photosensitizing lipid nanoparticles (PLNPs) capable of delivering glutathione peroxidase 4 (GPX4)‐targeting small interfering RNA (siRNA). Upon laser irradiation, the PLNPs generate reactive oxygen species (ROS) through PDT, while siRNA‐mediated GPX4 silencing promotes ferroptosis by disrupting cellular antioxidant defenses. The PLNPs demonstrate favorable physicochemical characteristics, efficient gene silencing, and potent ROS production. In vitro experiments in 4T1 and EO771 breast cancer cells reveal enhanced cytotoxicity under combined treatment, underscoring the synergistic interaction between PDT‐induced oxidative stress and ferroptotic cell death. In vivo, the PLNPs exhibit prolonged tumor retention, effective GPX4 knockdown, and significant tumor growth inhibition, with minimal systemic toxicity. Overall, this work introduces a dual‐function nanoplatform that potentiates photodynamic cancer therapy through ferroptosis induction and offers a versatile strategy for developing next‐generation combination treatments targeting aggressive tumors.
- Open Access
- 3 March 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (15) , e2404819
Dual‐Functional Hafnium Oxide Nanoplatform Combining High‐Z Radiosensitization With Bcl‐2 Gene Silencing for Enhanced Cancer Radiotherapy
The efficacy of radiotherapy is often limited by insufficient radiosensitization and tumor radioresistance. This study reports a dual‐functional hafnium oxide nanoplatform that combines high‐Z radiosensitization with Bcl‐2 gene silencing for enhanced cancer radiotherapy. The nanoplatform is developed by surface modification of hafnium oxide nanoparticles with polyethyleneimine, enabling efficient siRNA delivery while maintaining inherent high‐Z radiosensitizing properties. Comprehensive physicochemical characterization confirmed the successful surface modification and stable siRNA complexation. Upon radiation exposure, the nanoplatform enhanced reactive oxygen species generation and DNA damage while simultaneously delivering Bcl‐2 siRNA to suppress radioresistance mechanisms. In vitro studies revealed significant enhancement of radiation‐induced cell death through synergistic effects of high‐Z radiosensitization and Bcl‐2 silencing, evidenced by increased γ‐H2AX expression and apoptotic cell population. In a murine colon cancer model, the nanoplatform achieved remarkable tumor growth inhibition (80%) when combined with radiotherapy while exhibiting favorable biocompatibility in major organs. Mechanistic studies confirmed effective Bcl‐2 downregulation and enhanced DNA damage in tumor tissues, validating this dual‐functional therapeutic approach. This study presents a promising strategy for improving radiotherapy outcomes through the simultaneous enhancement of radiosensitization and suppression of radioresistance, potentially advancing the field of cancer radiotherapy.
- 3 March 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (15) , e2404819
Open AccessDual‐Functional Hafnium Oxide Nanoplatform Combining High‐Z Radiosensitization With Bcl‐2 Gene Silencing for Enhanced Cancer Radiotherapy
The efficacy of radiotherapy is often limited by insufficient radiosensitization and tumor radioresistance. This study reports a dual‐functional hafnium oxide nanoplatform that combines high‐Z radiosensitization with Bcl‐2 gene silencing for enhanced cancer radiotherapy. The nanoplatform is developed by surface modification of hafnium oxide nanoparticles with polyethyleneimine, enabling efficient siRNA delivery while maintaining inherent high‐Z radiosensitizing properties. Comprehensive physicochemical characterization confirmed the successful surface modification and stable siRNA complexation. Upon radiation exposure, the nanoplatform enhanced reactive oxygen species generation and DNA damage while simultaneously delivering Bcl‐2 siRNA to suppress radioresistance mechanisms. In vitro studies revealed significant enhancement of radiation‐induced cell death through synergistic effects of high‐Z radiosensitization and Bcl‐2 silencing, evidenced by increased γ‐H2AX expression and apoptotic cell population. In a murine colon cancer model, the nanoplatform achieved remarkable tumor growth inhibition (80%) when combined with radiotherapy while exhibiting favorable biocompatibility in major organs. Mechanistic studies confirmed effective Bcl‐2 downregulation and enhanced DNA damage in tumor tissues, validating this dual‐functional therapeutic approach. This study presents a promising strategy for improving radiotherapy outcomes through the simultaneous enhancement of radiosensitization and suppression of radioresistance, potentially advancing the field of cancer radiotherapy.
- 22 May 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (14) , e2200389
Flexible 3D Nanonetworked Silica Film as a Polymer‐Free Drug‐Eluting Stent Platform to Effectively Suppress Tissue Hyperplasia in Rat Esophagus
Loading and eluting drugs on self‐expandable metallic stents (SEMSs) can be challenging in terms of fabrication, mechanical stability, and therapeutic effects. In this study, a flexible 3D nanonetworked silica film (NSF) capable of withstanding mechanical stress during dynamic expansion is constructed to function as a drug delivery platform on an entire SEMS surface. Despite covering a broad curved area, the synthesized NSF is defect‐free and thin enough to increase the stent strut diameter (110 µm) by only 0.4 percent (110.45 µm). The hydrophobic modification of the surface enables loading of 4.7 times the sirolimus (SRL) concentration in NSF than Cypher, polymer‐coated commercial stent, which is based on the same thickness of coating layer. Furthermore, SRL‐loaded NSF exhibits a twofold delay in release compared to the control group without NSF. The SRL‐loaded NSF SEMS significantly suppresses stent‐induced tissue hyperplasia than the control SEMS in the rat esophagus (all variables, p < 0.05). Thus, the developed NSF is a promising polymer‐free drug delivery platform to efficiently treat esophageal stricture.
- 22 May 2022
- Published by Wiley in Advanced Healthcare Materials
- Vol. 11 (14) , e2200389
Flexible 3D Nanonetworked Silica Film as a Polymer‐Free Drug‐Eluting Stent Platform to Effectively Suppress Tissue Hyperplasia in Rat Esophagus
Loading and eluting drugs on self‐expandable metallic stents (SEMSs) can be challenging in terms of fabrication, mechanical stability, and therapeutic effects. In this study, a flexible 3D nanonetworked silica film (NSF) capable of withstanding mechanical stress during dynamic expansion is constructed to function as a drug delivery platform on an entire SEMS surface. Despite covering a broad curved area, the synthesized NSF is defect‐free and thin enough to increase the stent strut diameter (110 µm) by only 0.4 percent (110.45 µm). The hydrophobic modification of the surface enables loading of 4.7 times the sirolimus (SRL) concentration in NSF than Cypher, polymer‐coated commercial stent, which is based on the same thickness of coating layer. Furthermore, SRL‐loaded NSF exhibits a twofold delay in release compared to the control group without NSF. The SRL‐loaded NSF SEMS significantly suppresses stent‐induced tissue hyperplasia than the control SEMS in the rat esophagus (all variables, p < 0.05). Thus, the developed NSF is a promising polymer‐free drug delivery platform to efficiently treat esophageal stricture.